Loading stock data…
$28.37-0.03 (-0.11%)
Pfizer Inc.
Pfizer Inc. in the Healthcare sector is trading at $28.37 with a market capitalization of $159.7B. Wall Street consensus targets $29.26 (26 analysts), implying a +3.1% move over the next 12 months. The stock is currently near its 52-week high of $29.21, remaining 9.3% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15.03B↑ | $14.45B↓ | $17.56B↑ | $16.65B↑ | $14.65B |
| Gross Profit | $10.94B↑ | $10.90B↓ | $12.29B↓ | $12.48B↑ | $10.88B |
| Operating Income | $3.54B↓ | $4.27B↑ | $3.69B↓ | $5.53B↑ | $3.77B |
| Net Income | -$248.00M↓ | $2.69B↑ | -$1.65B↓ | $3.54B↑ | $2.91B |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine...
Academic risk and quality models computed from PFE's own filings and price history, not from analyst opinion.
Mixed: 6 of 9 fundamental-health tests pass, so profitability and balance-sheet trends disagree.
Altman Z in the 1.81 to 2.99 grey zone, the band where the model gives no clear bankruptcy verdict.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
Share of earnings coming from accruals rather than cash. Higher values historically precede weaker future returns.
GARCH(1,1) 30-day annualised forecast, above the current 22.0% reading.
Fama-French 5-factor market beta. The five factors explain 19% of this stock's return variance; the rest is idiosyncratic.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.
Model inputs as of 2026-10-13.